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Aim: To investigate the serum level of leptin (OB) and its relationship with pro- and antiinflammatory cytokines/mediators in aggressive
periodontitis (AP) patients.
Materials and methods: The study population (n = 12) comprised 6 AP patients and 6 periodontally healthy subjects (HC). The
fasting venous serum samples were used to determine the OB and the cytokines/mediators belonging to the Th1/Th2/Th17 cells. The
correlations among the OB and cytokines/mediators in the serum and clinical periodontal parameters were also investigated.
Results: The AP group presented significantly higher serum TGF-β1 and IL-2 concentrations (pg/mL) and lower IL-4, IL-5, IL-12, IL13, and IL-17A concentrations than the HC group (P < 0.05). The ratios of OB to IL-12, IL-13, and IL-17A were lower and the ratio of
OB to TGF-β1 was higher in the AP than in the HC group (P < 0.05).
Conclusion: Within the limitation of the small sample size, the results of our study are important in having determined the proportional
relationship of OB with the pro- and antiinflammatory cytokines’/mediators’ panel in AP patients. The usage of these kits in analyzing
multiple cytokines/mediators might proportionally clarify the pathogenesis of AP.
Key words: Aggressive periodontitis, leptin, cytokines

1. Introduction
The cytokines affect various cells and play important roles
in various inflammatory diseases such as periodontitis
(1). They have roles in the function and differentiation
of T cells, and they designate the T-helper subsets to
amplify or control the amplitude of the inflammation
and the destruction related to inflammation (2,3). The
macrophages and T cells are dominate in the early/stable
lesions of chronic periodontitis (CP), leading to the
consideration that this response is developed by the Th1
cytokines. In the advanced/progressive lesions of CP, B
cells and plasma cells are dominate and present the Th2
cytokines (1,2). Intriguingly, aggressive periodontitis
(AP) was not the focus of the studies investigating the
dominance of Th cell types. However, supporting the
information above, it was suggested that AP lesions should
present the predomination of Th2 because of its B cellplasma cell nature (4).
It was suggested that the above-mentioned Th1/Th2
model could not be adequate to explain the complex
interactions between the cytokines and immune cells (5).
* Correspondence: zuhalyetkin@yahoo.com

Recently, Th17 cells gained considerable attention with
their cytokine profiles. In the Th17 cell development and
IL-17 production, transforming growth factor (TGF)-β
and IL-23 are determinants; it was revealed that the Th1
response could be decreased by the presence of IL-23 (6).
Moreover, IL-12 or IL-4 can influence the Th17 cells to
convert Th1 or Th2 cells (7).
Growth factors, hormones, and chemokines are the
other immunoregulatory molecules that regulate the
development and progression of periodontal diseases.
Leptin (OB) is one of these immunomodulatory
molecules. OB is one of the adipokines that have an effect
on food intake and energy consumption. It is a 16-kDa
nonglycosylated peptide, similar to those in the IL-6
family (8). Furthermore, it has been reported that OB has
an immunomodulatory effect (9). The host response was
mediated by OB in a proinflammatory way, activating
the proinflammatory cells to produce proinflammatory
cytokines (10,11).
In our previous study, OB and soluble OB receptors
(s-OB-Rs) were investigated in the gingiva and in the
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serum of AP patients. The presence of OB and s-OB-R in
the gingiva supported our hypothesis that these molecules
may have a regulatory role in periodontal diseases and
in AP pathogenesis (12). We suggested in our previous
study, in light of our results, that further studies were
needed in terms of the ratio of OB to the key cytokines,
evidenced to play major roles in the periodontal disease
pathogenesis, to possibly clarify their role in periodontal
disease pathogenesis.
Similar to CP, in AP it is logical to investigate the
balance, ratio, and relationship between the cytokine
and immunomodulatory molecules (growth factors,
hormones, chemokines, etc.) to clarify the etiology and
pathogenesis of AP, since the pro- and antiinflammatory
cytokines and other immunomodulatory molecules are
produced and secreted by the same immune cells as in
CP. In the present study, we investigated the proportional
relationship of OB and key cytokines/mediators in a group
of AP patients and compared them to a healthy control
group (HC) using a multiple cytokine analysis kit.
2. Materials and methods
This study was conducted according to the ethical
standards of the Declaration of Helsinki (Version VI,
2002). The details of study were explained and written
consent was obtained from the subjects. In addition, the
Ethics Committee of the Süleyman Demirel University
Faculty of Medicine approved the study (6068, 22.12.2005).
The volunteers were selected from subjects referred to
the Süleyman Demirel University Faculty of Dentistry
and Department of Periodontology between December
2005 and December 2008. The study population consisted
of individuals from our previous study (12). Both of the
groups (AP and HC groups) consisted of the first 6 people
who participated the previous study. The diagnosis of
the periodontal status was made regarding the criteria
reported in the Consensus Classification of Periodontal
Diseases (13).
2.1. Study population
Patients having systemic diseases (diabetes mellitus,
cardiovascular disease, respiratory system diseases,
osteoporosis, etc.), using drugs (antidepressants,
antiinflammatory, antidiabetic, antihyperlipidemic, etc.)
routinely, using antibiotics (in the last 3 months), or
receiving periodontal treatment (in the last 6 months)
were excluded from the study. The pregnant and lactating
female subjects were also excluded. All of the subjects who
participated in this study were nonsmokers.
2.2. Periodontal examination and recordings
The periodontal recordings, including gingival index (GI)
(14), plaque index (PI) (15), bleeding on probing (BOP)
(16), and probing depth (PD) and clinical attachment level
(CAL) values, were recorded by a single examiner (ZYA)
with 85% accuracy of measurements.
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2.3. Biochemical analysis
The fasting blood samples (8 mL) were obtained in the
morning. The blood samples were centrifuged (5 min at
5000 rpm), and the separated serum was portioned. The
serum samples were stored at –80 °C until the analysis.
Commercial ELISA kits were used to evaluate the levels
of OB and the cytokine/mediator in serum samples
(Biovendor, Czech Republic; Multi-Analyte ELISArray,
SABioscience, USA).
2.4. Statistical analysis
Continuous variables were presented as median
(minimum–maximum), and the categorical variables were
presented as frequencies. The Mann–Whitney U test was
used to analyze the differences between 2 groups (P <
0.05). The correlations between parameters were evaluated
using the Spearman rho correlation coefficient (P < 0.05).
The analyses were made using SPSS 9.0 (SPSS Inc., USA).
3. Results
Both of the groups consisted of 6 people (4 females, 2 males
in the AP group; 3 females, 3 males in the HC group). The
age ranges were 35–43 years (mean: 38.67 ± 3.50) in the
AP group and 26–38 years (mean: 32.33 ± 4.13) in the
HC group. The BMI values of the groups were as follows:
23.20 (20.70–34.30) in AP and 25.78 (19.40–34.60) in HC.
The age and BMI values were not found to be significantly
different between the groups (P < 0.05).
3.1. Clinical parameters
All of the clinical parameters were significantly higher in
the AP group than the HC group (P < 0.05, Table 1).
3.2. Serum OB levels
The serum OB levels were 17.20 (8.49–43.30) in the AP
group and 12.67 (6.76–22.36) in the HC group (pg/mL,
median, minimum–maximum), and were not statistically
significantly different (P > 0.05).
3.3. Cytokine and mediator levels and leptin/cytokine
(mediator) ratios
In the AP group, the serum TGF-β1 and IL-2 concentrations
(pg/mL) were significantly higher and the IL-4, IL-5, IL12, IL-13, and IL-17A concentrations were significantly
lower than in the healthy control group (P < 0.05, Figure).
The OB/cytokine (mediator) ratios presented significant
differences between the groups, as shown in Table 2.
Briefly, the ratios of leptin to IL-12, IL-13, and IL-17A
were lower and that to TGF-β1 was higher in the AP than
the HC group (P < 0.05, Table 2).
3.4. Correlations
The statistically significant correlations between the
parameters are presented in Table 3. All of the clinical
parameters showed positive correlations with IL-12 (P <
0.05) and negative correlations with IL-17a and TGF-β1
(P < 0.05). The BMI values did not present any significant
correlations with clinical and serum parameters (P > 0.05).
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Table 1. The periodontal characteristics.
Groups/parameters

AP (n = 6)

HC (n = 6)

P

GI

1.85
(1.07–2.44)

0.22
(0–0.39)

*

PI

1.89
(1.26–2.67)

0.37
(0–0.87)

*

BOP (%)

93.65
(61.90–100)

13.98
(0–30.43)

*

PD (mm)

4.32
(3.55–5.18)

1.52
(1.41–2.27)

*

CAL (mm)

5.89
(5.33–6.81)

1.82
(0–2.27)

*

*: Significantly different (Mann–Whitney U test, P < 0.05).

Serum levels (pg/mL)

700
600
500
400
300
200
100
0
AP (n = 6)

IL-2

IL-4

IL-5

IL-12

IL-13

75.67

81.5

93.17

11.67

19.83

27

190.67

62.33

124

2.47

3.97

7.35

578.5

HC (n = 6) 44.33

IL-17A TGF-β

cytokines/mediators

Figure. The serum cytokine and mediator levels (median) in the groups.

Table 2. The statistically significantly different OB/cytokine (mediator) ratios.
AP (n = 6)

HC (n = 6)

P

OB/IL-12

1.57 (0.61–4.33)

5.23 (2.33–9.35)

*

OB/IL-13

0.92 (0.39–2.41)

3.25 (1.42–5.88)

*

OB/IL-17A

0.68 (0.27–1.88)

1.75 (0.79–2.98)

*

OB/TGF-β

0.10 (0.04–0.28)

0.02 (0.01–0.04)

*

*: Significantly different (Mann–Whitney U test, P < 0.05).

4. Discussion
To our knowledge, this is the first study that evaluated
the serum OB levels proportionally to multiple cytokines/
mediators in AP patients. These assays could be used in
future studies to achieve a rough perspective about the
relationship between the pro- and antiinflammatory
cytokines/mediators in the pathogenesis of CP and AP.

These assays could also be used to clarify the transition
from the healthy state to gingivitis and from gingivitis
to periodontitis. The individuals at risk for periodontitis,
the presence of a subclinical disease, the diagnosis, the
determination of disease activity, and the response to
the treatment and the selection of therapies might be
determined by the usage of such a biomarker panel.
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Table 3. The significant correlations.
rho

P

IL-12 - TGF-β

–0.767 **

0.004

BOP - G-CSF

–0.614 *

0.033

GI - TGF-β

–0.636 *

0.026

PI - TGF-β

–0.683 *

0.014

BOP - TGF-β

–0.827 **

0.001

PD - TGF-β

–0.692 *

0.013

CAL - TGF-β

–0.720 **

0.008

GI - IL-12

0.886 **

0.000

PI - IL-12

0.775 **

0.003

BOP - IL-12

0.726 **

0.007

PD - IL-12

0.764 **

0.004

CAL - IL-12

0.781 **

0.003

GI - OB/IL-17A

–0.818 **

0.001

PI - OB/IL-17A

–0.848 **

0.000

BOP - OB/IL-17A

–0.638 *

0.026

PD - OB/IL-17A

–0.594 *

0.042

CAL - OB/IL-17A

–0.664 *

0.018

GI - OB/IL-2

–0.580 *

0.048

BOP - OB/IL-12

–0.674 *

0.016

PD - OB/IL-12

–0.636 *

0.026

CAL - OB/IL-12

–0.678 *

0.015

BOP - OB/TGF-β

0.725 **

0.008

PD - OB/TGF-β

0.762 **

0.004

CAL - OB/TGF-β

0.706 *

0.010

Parameters

Spearman’s correlation test (*: P < 0.05, **: P < 0.01).

Another important advantage of these kits is the
relatively ideal working conditions. Ideally, for reliable
results the same conditions are preferred. For example, all
of the kits (12 different ELISA kits for 12 different serum
parameters) are preferred to be used at the same time of
day, under the same laboratory conditions (at the same
temperature and humidity), and by the same person.
These conditions (same person, same time interval, same
temperature, etc.) could not be achieved in our studies
when investigating more than 3 parameters (cytokines/
mediators). In addition to having the advantages
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mentioned above, these assays used in the present study
are easy to use and with their low costs they are candidates
to be more expansive. However, we agree with Thunell
et al. (17), who stated that it was important to consider
interassay disparities in terms of the particular technique
that was used (i.e. multiplex bead assays or ELISA kits)
used and possible interlaboratory variations. It should also
be kept in mind that it would be logical not to compare the
results that belong to one assay to another assay used in
different studies (18).
With this preliminary study, we have obtained a general
perspective about the proportional balance between OB
and cytokines/mediators. Although the very limited study
sample would not give the opportunity to make clear
comments about this issue, some results were intriguing.
In the present study, the serum OB levels were similar in
both of the groups, and the ratios of OB to some cytokines/
mediators (IL-12, IL-13, IL-17A, and TGF-β1) were found
to be significantly different. These significant differences
depend on the significantly different concentrations of
these cytokines and growth factor between the groups.
Despite the insignificantly different serum OB levels in the
AP and HC groups, we speculate that an “alternate leptin
pathway” exists, as we suggested in our previous study
(12). This “alternate leptin pathway” might be regulated by
these above-mentioned factors (IL-12, IL-13, IL-17A) and
by other cytokines.
By the usage of the multiple cytokine/mediator analysis
kit in this study, the Th1, Th2, and Th17 cells and their
cytokine/mediator productions are dependent upon each
other with various routes in periodontitis, and also in AP
patients. In addition, the correlations between the clinical
parameters and IL-12, IL-17, and TGF-β have led us to
consider that there is an imbalance towards the Th2 type
of reaction in AP to avoid the destruction directed toward
the host tissues.
The Th1/Th2 balance was reported to be regulated by
IL-12 in favor of the Th1-specific manner, with concomitant
production of interferon (IFN)-γ, IL-1β, tumor necrosis
factor (TNF)-α, and IL-8 from T cells and natural killer
cells. Thus, the early innate immune response shifted to
the adaptive immune response (19).
The role of IL-13 in periodontitis was not clarified.
In periodontitis lesions, the expression of IL-13 was
demonstrated (19,20). IL-4 and IL-13 have effects
on fibroblasts by activating TGF-β production in
macrophages (21). The localized absence of IL-4 in
periodontally diseased tissues was reported to be related
to the periodontal disease activity and progression (22).
In the present study, the serum IL-4 and IL-13 levels were
higher in AP patients than in the HC group, which led
to the consideration that the AP lesions have a balance
towards Th2 reaction because of the B cells’ predominance.
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It was previously reported that IL-4 might be classified as a
B-cell growth factor (23).
The serum level of IL-17 of AP patients was found
higher than that of the HC group in the present study.
The proinflammatory nature of IL-17 was also reported
(24,25). TGF-β and IL-6 presences have modulated the
naive T cells to differentiate to Th17 (5). IL-12 or IL-4 has
been reported to affect the TH17 cells to differentiate to
Th1 or Th2 cells (6). IL-23 regulates the Th1 differentiation
from Th17 negatively (5). Unfortunately, the cytokine/
mediator panel used in our study did not include IL-23 to
enhance our comments on this regulatory role of IL-23 on
the Th1 response inhibited by IL-17.
In the present study, the serum level of TGF-β in the
AP group was lower than in the HC group. The functional
properties of TGF-β were determined and reported as cell
growth regulation, differentiation and matrix production,
and remodeling in both soft and mineralized connective
tissues (26,27).
The roles and functions of the cytokines and mediators,
which were significantly different between the serum
samples of AP and HC subjects, were concluded above. In
this regard, it is obvious that a balance between Th1/Th2 and
Th17 cells and cytokines in periodontal disease exists. It is
necessary to investigate this balance with its components
(cytokines/mediators and cells) in the pathogenesis of
AP. The studies should focus on these interactions, and
accordingly on the balance and imbalance between these
cells types and their productions, the key mediators
regulating the events in inflammation in the initiation
and progression, not only in CP but also in AP. The results
obtained from these studies allow researchers to develop

new treatment strategies based on the findings, such as
immunomodulatory therapies. Larger study groups are
required to investigate the levels of OB and Th1/Th2/Th17
cytokines/mediators in gingival crevicular fluid, serum,
and gingival tissues of AP patients.
Conclusively, within the limited sample size of the
present study, OB did not present a significant difference
between the groups. When the levels of serum OB in the
AP (17.20 pg/mL) and in the HC (12.67 pg/mL) groups
are taken into consideration, it might be speculated that
the difference might be significant if the sample size
were larger. However, the presence of leptin reported in
the gingiva of the AP patients in our previous study (12)
led us to consider that OB levels might have an effect on
periodontal inflammation of AP patients and might be
regulated by the cytokines/mediators, standing on the
forefront in the results of the present study. In further
studies, the study population should be subgrouped not
only according to the periodontal status (healthy and AP),
but also to systemic status, and especially the presence
of diabetes (the levels of some cytokines/mediators were
found to be significantly different in diabetic subjects than
in healthy subjects) (28,29)). The study population should
also be organized according to the serum lipid profiles, to
the different BMI values, and the body fat mass and hip/
wrist ratio, which may provide more accurate information
about the role of OB in AP pathogenesis.
Acknowledgments
This study was supported by the Scientific and
Technological Research Council of Turkey (TÜBİTAK,
project number: 106S187 SBAG 3435).

References
1.

Yamazaki K, Nakajima T, Kubota Y, Gemmell E, Seymour
GJ, Hara K. Cytokine messenger RNA expression in chronic
inflammatory periodontal disease. Oral Microbiol Immunol
1997; 12: 281–7.

6.

Zelante T, De Luca A, Bonifazi P, Montagnoli C, Bozza S, Moretti
S et al. IL-23 and the Th17 pathway promote inflammation and
impair antifungal immune resistance. Eur J Immunol 2007; 37:
2680–2.

2.

Gemmell E, Winning TA, Grieco DA, Bird P, Seymour GJ. The
influence of genetic variation on the splenic T cell cytokine
and specific serum antibody responses to Porphyromonas
gingivalis in mice. J Periodontol 2000; 71: 1130–8.

7.

Lexberg MH, Taubner A, Forster A, Albrecht I, Richter A,
Kamradt T et al. Th memory for interleukin-17 expression is
stable in vivo. Eur J Immunol 2008; 38: 2654–64.

8.

3.

Houri-Haddad Y, Wilensky A, Shapira L. T-cell phenotype as a
risk factor for periodontal disease. Periodontol 2000 2007; 45:
67–75.

Zhang YR, Proence M, Maffei M, Barone M, Leopold L,
Friedman JM. Positional cloning of the mouse obese gene and
its human homologue. Nature 1994; 372: 425–31.

9.

Zarkesh-Esfahani H, Pockley AG, Wu Z, Hellewell PG,
Weetman AP, Ross RJ. Leptin indirectly activates human
neutrophils via induction of TNF-α. J Immunol 2004; 172:
1809–14.

4.

Ford PJ, Gamonal J, Seymour GJ. Immunological differences
and similarities between chronic periodontitis and aggressive
periodontitis. Periodontol 2000 2010; 53: 111–23.

5.

Gaffen SL, Hajishengallis G. A new inflammatory cytokine on
the block: re-thinking periodontal disease and the Th1/Th2
paradigm in the context of Th17 cells and IL-17. J Dent Res
2008; 87: 817–28.

10. Ahima RS, Flier JS. Leptin. Ann Rev Physiol 2000; 62: 413–37.
11. Hristova M, Aloe L, Ghenev PI, Fiore M, Chaldakov GN. Leptin
and mast cells: a novel adipoimmune link. Turk J Med Sci 2001;
31: 581–3.

829

YETKİN AY et al. / Turk J Med Sci
12. Yetkin Ay Z, Kırzıoğlu FY, Öztürk Tonguç M, Sütçü R,
Kapucuoğlu N. The gingiva contains leptin and leptin receptor
in health and disease. Odontology 2012; 100: 222–31.
13. Armitage GC. Development of a classification system for
periodontal diseases and conditions. Ann Periodontol 1999; 4:
1–6.
14. Löe H, Silness J. Periodontal disease in pregnancy. I. Prevalence
and severity. Acta Odontol Scand 1963; 21: 533–51.
15. Silness J, Löe H. Periodontal disease in pregnancy. II.
Correlation between oral hygiene and periodontal condition.
Acta Odont Scand 1964; 22: 121–35.
16. Ainamo J, Bay I. Problems and proposals for recording gingivitis
and plaque. Int Dent J 1975; 25: 229–35.
17. Thunell DH, Tymkiw KD, Johnson GK, Joly S, Burnell KK,
Cavanaugh JE et al. A multiplex immunoassay demonstrates
reductions in gingival crevicular fluid cytokines following
initial periodontal therapy. J Periodontal Res 2010; 45: 48–52.
18. Fichorova RN, Richardson-Harman N, Alfano M, Belec L,
Carbonneil C, Chen S et al. Biological and technical variables
affecting immunoassay recovery of cytokines from human
serum and simulated vaginal fluid: a multicenter study. Ann
Chem 2008; 80: 4741–51.
19. Trincheri G, Gerosa F. Immunoregulation by interleukin-12. J
Leukoc Biol 1996; 59: 505–11.
20. Trincheri G. Interleukin-12 and the regulation of innate
resistance and adaptive immunity. Nature Rev Immunol 2003;
3: 133–46.
21. de Waal M, Figdor CG, Huijbens R, Mohan-Peterson S, Bennett
B, Culpepper J et al. Effects of IL-13 on phenotype, cytokine
production, and cytotoxic function of human monocytes.
Comparison with IL-4 and modulation by IFN-gamma or IL10. J Immunol 1993; 151: 6370–81.

830

22. Nakajima T, Yamazaki K, Cullinan MP, Gemmell E, Seymour
GJ. T-cell antigen specificity in humans following stimulation
with Porphyromonas gingivalis. Arch Oral Biol 1999; 44:
1045–53.
23. Shapira L, van Dyke TE, Hart TC. A localized absence of
interleukin-4 triggers periodontal disease activity: a novel
hypothesis. Med Hypotheses 1992; 39: 319–22.
24. Kolls JK, Linden A. Interleukin-17 family members and
inflammation. Immunity 2004; 21: 467–76.
25. Kramer JM, Gaffen SL. Interleukin-17: a new paradigm in
inflammation, autoimmunity, and therapy. J Periodontol 2007;
78: 1083–93.
26. Gürkan A, Emingil G, Çınarcık S, Berdeli A. Gingival
crevicular fluid transforming growth factor-β1 in several forms
of periodontal disease. Arch Oral Biol 2006; 51: 906–12.
27. Prime SS, Pring M, Davies M, Paterson IC. TGF-β signal
transduction in oro-facial health and non-malignant disease
(Part I). Crit Rev Oral Biol Med 2004; 15: 324–36.
28. Correa FOB, Gonçalves D, Figueredo CMS, Bastos AS,
Gustafsson A, Orrico SRP. Effect of periodontal treatment on
metabolic control, systemic inflammation and cytokines in
patients with type 2 diabetes. J Clin Periodontol 2010; 37: 53–8.
29. Filkova M, Haluzik M, Gay S, Senolt L. The role of resistin as
a regulator of inflammation: implications for various human
pathologies. Clin Immunol 2009; 133: 157–70.

